共 830 条
[71]
Yaeger R(2016)Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts) J Clin Oncol 34 1086-undefined
[72]
Segal NH(2016)Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine J Immunother Cancer 4 25-undefined
[73]
Ku GY(2019)PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review Breast Cancer Res Treat 174 571-undefined
[74]
DeMatteo R(2018)Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy? Cell Biosci 8 34-undefined
[75]
Ladanyi M(2018)PD-L1 Immunohistochemistry comparability study in real-life clinical samples: results of Blueprint Phase 2 Project J Thoracic Oncol 13 1302-undefined
[76]
Rizvi NA(2019)Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + <em>nab</em>-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer Cancer Research 79 GS1-04-GS1-undefined
[77]
Berger MF(2016)Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients Cancer Sci 107 1730-undefined
[78]
Riaz N(2018)Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer J Clin Oncol 36 1010-undefined
[79]
Solit DB(2015)PD-1 blockade in tumors with mismatch-repair deficiency N Engl J Med 372 2509-undefined
[80]
Chan TA(1999)Microsatellite instability is uncommon in breast cancer Clin Cancer Res 5 839-undefined